Dr. Reddy?s Laboratories announces entering into a definitive agreement tosell its neurology branded products to Upsher-Smith Laboratories, LLC
Hyderabad, India and Princeton, NJ, USA. June 14, 2019 - Dr. Reddy?s Laboratories Limited (BSE:
500124, NSE: DRREDDY, NYSE: RDY), announces that it has entered into a definitive asset purchase
agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which Dr. Reddy?s would sell
its US and select territory rights for ZEMBRACE? SYMTOUCH? (sumatriptan injection) 3 mg and
TOSYMRATM (sumatriptan nasal spray) 10 mg, (formerly referred to as ?DFN-02?), which are
commercialized through its wholly owned subsidiary, Promius Pharma, LLC.
Under the agreement, Dr.Reddy?s will receive U.S.$70 million as upfront consideration, U.S.$40.5 million
in near term milestones and additional financial considerations including, existing contractual obligation
and inventory. Subsequently, Dr. Reddy?s will receive sales based royalties on a quarterly basis.
The closing of the transaction is subject to various customary closing conditions including antitrust review
under Hart-Scott-Rodino Act.
?This is a testament to our strong R&D capabilities, and delivering solutions to unmet needs of patients. In
a short time, we created a well-recognized migraine specialty business in the US and we look forward to
our partnership with Upsher-Smith? said G.V. Prasad, Co-Chairman and CEO, Dr. Reddy?s Laboratories
Limited.
?Tosymra and Zembrace were designed and developed with the goal of addressing unmet needs of large
but discrete segments of patients suffering from episodic migraine who need options other than their
current therapies. We are excited to partner with Upsher-Smith which has established a strong presence
in neurology? said Anil Namboodiripad, Ph.D., Senior Vice President, Proprietary Products and Head,
Promius Pharma.
Important Patient Safety Information for Zembrace SymTouch (sumatriptan injection) 3 mg and
TOSYMRA (sumatriptan nasal spray) 10 mg.
Zembrace SymTouch and TOSYMRA can cause serious side effects, including: heart attack and
other heart problems, which may lead to death.
Do not use Zembrace SymTouch and TOSYMRA if you have:
? heart problems or a history of heart problems
? narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
? uncontrolled high blood pressure
? severe liver problems
? hemiplegic migraines or basilar migraines. If you are not sure if you have these, ask your healthcare
provider
? had a stroke, transient ischemic attacks (TIAs), or problems with your blood circulation
? taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan,
naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your healthcare provider if you are not
sure if your medicine is listed above
? are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2
weeks or less since you stopped taking a MAO-A inhibitor. Ask your healthcare provider or pharmacist
for a list of these medicines if you are not sure.
? an allergy to sumatriptan or any of the ingredients in Zembrace SymTouch and TOSYMRA.
You are encouraged to report negative side effects of prescription drugs. To report SUSPECTED
SIDE EFFECTS, call Promius Pharma at 1-888-966-8766 or contact the FDA at 1-800-FDA-1088 (1-
800-332-1088) or online at http://www.fda.gov/Safety/MedWatch
Please see Full Prescribing Information for Zembrace SymTouch and TOSYMRA.
For more information, please visit www.zembrace.com and www.mytosymra.com